NEW YORK (GenomeWeb) – Following Invitae's announcement earlier this week that its first quarter revenues rose sharply year over year, investment bank Leerink today upgraded shares of the company to an Outperform rating. 

Analyst Dan Leonard upgraded the San Francisco-based molecular diagnostics firm from a prior Market Perform rating but kept the price target on its shares at $20.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.